• PDF / 169,637 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 65 Downloads / 152 Views

DOWNLOAD

REPORT

---

1

S

Peripheral neuropathy: case report A retrospective study of 58 men with castration resistant prostate cancer, who received carboplatin and paclitaxel between 2001 and 2018, described a man [age not stated], who developed peripheral neuropathy during treatment with carboplatin and paclitaxel for castration resistant prostate cancer. The man, who had previously received docetaxel and cabazitaxel for castration resistant prostate cancer, started receiving third-line treatment with IV paclitaxel 175 mg/m2 over 3 hours, followed by carboplatin (area under the curve: 5 mg/mL/minute) on day 1 of a 28-day cycle. Thereafter, he developed grade 3 peripheral neuropathy [duration of treatment to reaction onset not stated]. He had received four cycles of carboplatin and paclitaxel therapy [outcome not stated]. Author comment: "[W]e retrospectively studied the efficacy and safety of [carboplatin and paclitaxel]". "Neutropenia (58.6%) and neuropathy (43.1%) were the most common [adverse events]". "There was 1 case of grade 3 peripheral neuropathy". Fujiwara M, et al. Efficacy and Safety of Carboplatin Plus Paclitaxel as the First-, Second-, and Third-line Chemotherapy in Men With Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer 17: e923-e929, No. 5, Oct 2019. Available 803433227 from: URL: http://doi.org/10.1016/j.clgc.2019.04.017 - Japan

0114-9954/19/1778-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved

Reactions 9 Nov 2019 No. 1778